相关实验视频

Updated: Jan 13, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

在乳腺癌的新辅助疗法中提高甲福明的疗效:基于随机临床试验的元分析

Fei Xie¹, Ting Jiang², Mengyi Qian³

¹Department of Endocrinology, Ningbo Yinzhou No. 2 Hospital, Ningbo, China.

Cancer control : journal of the Moffitt Cancer Center

|October 29, 2025

概括

这次元分析发现,将甲福明添加到新辅助性乳腺癌治疗中并没有显著改善病理完整反应率. 需要进一步的研究来探索甲胺.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

乳腺癌 (BC) 的新辅助治疗旨在在手术前减少瘤大小.
在临床前研究中,一种常见的糖尿病药物甲胺已经显示出潜在的抗癌作用.
在BC新辅助疗法中,甲福明对病理完整反应 (pCR) 的影响需要进一步研究.

研究的目的:

评估甲福明作为新辅助乳腺癌治疗中的辅助疗法的疗效.
为了确定甲福明是否会增加乳腺癌患者的病理完整反应 (pCR) 率.

主要方法:

在PubMed,Web of Science,Embase和Cochrane图书馆数据库中进行了系统的文献搜索.
包括到2025年4月发表的随机对照试验 (RCT).
计算pCR率的风险比率 (RR) 和95%置信区间 (CI).

主要成果:

八个与474名患者的RCT被纳入了这次元分析.
在甲福明和对照组之间没有观察到pCR率的统计学上显著差异 (RR = 1.21,95% CI: [0.85,1.71],P = 0.28).
在患有/没有代谢综合征的患者和来自东方/西方国家的亚组分析也显示没有显著差异.

结论:

在新辅助性乳腺癌治疗中增加甲福明的使用并没有对病理完整反应率产生显著影响.
目前的证据不支持在这种情况下使用甲福明作为增强pCR的手段.
可能需要进一步的研究来探索特定的患者亚组或替代治疗策略.

关键词:

这就是为什么BCBCBCBCBC 这是一个元分析.甲胺是一种甲胺.新辅助疗法是一种新辅助疗法.在 pCR 中,pCR 值为 pCR.

更多相关视频

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...